MODERNIZED ASPECTS OF MANAGEMENT PATIENTS WITH RESTENOSIS

##plugins.themes.academic_pro.article.sidebar##

Published Jun 17, 2023
Download
PDF
Statistic
Vol. 2 No. 6 (2023): Journal of Integrated Education and Research

##plugins.themes.academic_pro.article.main##

Maxmudov N.M., Ruziyeva A.A., Muinova K.K., Rustamova S.B.
Samarkand regional branch of the Specialized Scientific and Practical Medical Center of Cardiology

Abstract

Over the past 50 years, many countries of the world have distinguished themselves by their economically rapid growth and development, which served as the basis for dividing them into the following groups: developed and developing. This fact leads to significant changes in both living conditions for the better, and directly increases the quality of life. In turn, the factors provoking the occurrence of atherosclerotic changes are the following types: adherence to an unhealthy lifestyle, in particular to an unhealthy diet; a high rate of arterial hypertension; hypodynamic work and lifestyle in general, smoking and all other risk factors designated as bad habits. These include atherosclerosis of the cardiovascular system (CVS), which was the definition of coronary heart disease (CHD). It is this above-mentioned nosology that acts as a leader in the level of death and disability in the countries of the world [1,3,5]. Percutaneous intervention (PCI) as the most widely used, in particular, the method of CV stenting, for therapeutic purposes of various forms of coronary artery disease, leading to a progressive increase in the number of restenoses, this method is currently the most urgent problem of interventional cardiology [2,4,7]. A reliably established frequency of restenosis, after PCI, is not such an easy task. Many reliable sources say that during the period before the creation of coronary stents, after balloon angioplasty, the frequency of restenosis reaches 38-58%.

##plugins.themes.academic_pro.article.details##

How to Cite
Maxmudov N.M., Ruziyeva A.A., Muinova K.K., Rustamova S.B. (2023). MODERNIZED ASPECTS OF MANAGEMENT PATIENTS WITH RESTENOSIS. Journal of Integrated Education and Research, 2(6), 5–11. Retrieved from https://ojs.rmasav.com/index.php/ojs/article/view/1122

References

  1. World Health Organization. WHO Methods and data Sources for Country-Level Causes of Death 2000—2012.Geneva,Switzerland:WHO;2014.Accessed March 09, 2021.
  2. Byrne RA, Joner M, Kastrati A. Stent thrombosis and restenosis: what have we learned and where are we going? The Andreas Gruntzig Lecture ESC 2014. European Heart Journal. 2015;36(47):3320-3331.
  3. Fischman DL, Leon MB, Baim DS, Schatz RA, Savage MP, Penn I, Detre K, Veltri L, Ricci D, Nobuyoshi M. A randomized comparison of coronary-stent placement and balloon angioplasty in the treatment of coronary artery disease. Stent Restenosis Study Investigators. The New England Journal of Medicine. 1994;331(8):496-501.
  4. Kirtane AJ, Gupta A, Iyengar S, Moses JW, Leon MB, Applegate R, Brodie B, Hannan E, Harjai K, Jensen LO, Park SJ, Perry R, Racz M, Saia F, Tu JV, Waksman R, Lansky AJ, Mehran R, Stone GW. Safety and efficacy of drug-eluting and bare metal stents: comprehensive meta-analysis of randomized trials and observational studies. Circulation. 2009;119(25):3198-3206.
  5. Cortese B, Berti S, Biondi-Zoccai G, Colombo A, Limbruno U, Bedogni F, Cremonesi A, Silva PL, Sgueglia GA; Italian Society of Interventional Cardiology. Drug-coated balloon treatment of coronary artery disease: a position paper of the Italian Society of Interventional Cardiology. Catheterization and Cardiovascular Interventions. 2014;83(3):427-435.
  6. Buccheri D, Piraino D, Andolina G, Cortese B. Understanding and managing in-stent restenosis: a review of clinical data, from pathogenesis to treatment. Journal of Thoracic Disease. 2016;8(10):1150-1162. https://doi.org/10.21037/jtd.2016.10.93
  7. Roubin GS, King SB III, Douglas JS Jr. Restenosis after percutaneous transluminal coronary angioplasty: the Emory University Hospital experience. The American Journal of Cardiology. 1987;60(3):39-43.
  8. Cutlip DE, Windecker S, Mehran R, Boam A, Cohen DJ, van Es GA, Steg PG, Morel MA, Mauri L, Vranckx P, McFadden E, Lansky A, Hamon M, Krucoff MW, Serruys PW; Academic Research Consortium. Clinical end points in coronary stent trials: A case for standardized definitions. Circulation. 2007;115(17):2344-2351.
  9. Cassese S, Byrne RA, Schulz S, Hoppman P, Kreutzer J, Feuchtenberger A, Ibrahim T, Ott I, Fusaro M, Schunkert H, Laugwitz KL, Kastrati A. Prognostic role of restenosis in 10 004 patients undergoing routine control angiography after coronary stenting. European Heart Journal. 2015;36(2):94-99.
  10. Bossi I, Klersy C, Black AJ, Cortina R, Choussat R, Cassagneau B, Jordan C, Laborde JC, Laurent JP, Bernies M, Fajadet J, Marco J. In-stent restenosis: long-term outcome and predictors of subsequent target lesion revascularization after repeat balloon angioplasty. Journal of the American College of Cardiology. 2000;35(6):1569-1576.
  11. Nicolais C, Lakhter V, Virk HUH, Sardar P, Bavishi C, O’Murchu B, Chatterjee S. Therapeutic Options for In-Stent Restenosis. Current Cardiology Reports. 2018;20(2):7.
  12. Chen MS, John JM, Chew DP, Lee DS, Ellis SG, Bhatt DL. Bare metal stent restenosis is not a benign clinical entity. American Heart Journal. 2006;151(6):1260-1264.
  13. Dangas GD, Claessen BE, Caixeta A, Sanidas EA, Mintz GS, Mehran R. In-stent restenosis in the drug-eluting stent era. Journal of the American College of Cardiology. 2010;56(23):1897-1907.
  14. Magalhaes MA, Minha S, Chen F, Torguson R, Omar AF, Loh JP, Escarcega RO, Lipinski MJ, Baker NC, Kitabata H, Ota H, Suddath WO, Satler LF, Pichard AD, Waksman R. Clinical presentation and outcomes of coronary in-stent restenosis across 3-stent generations. Circulation. Cardiovascular Interventions. 2014;7(6):768-776.
  15. Aghababyan, I. R., Ismailov, J. A., & Ruziyeva, A. A. (2020). Chronic heart failure in young obese patients with chronic obstructive pulmonary disease. Achievements of science and education, (3 (57)), 84-87.
  16. Pulatov, Sh. Sh., Ruziyeva, A. A., & Khasanzhanova, F. O. (2023). Aspects Of Cardioprotection Of Patients With Chronic Heart Failure As A Consequence Of Myocardial Infarction. Periodica Journal of Modern Philosophy, Social Sciences and Humanities, 17, 133-136.
  17. Nizamov, H. S., Rakhmatzhanovna, Z., & Ruziyeva, A. A. (2023). Pandemic Features of Chronic Heart Failure in Young Patients. Periodica Journal of Modern Philosophy, Social Sciences and Humanities, 17, 155-158.
  18. Askarov, I. K., Kushnazarov, R. S., Ruziyeva, A. A., & Khasanzhanova, F. O. (2023). Predictors Of Cardioprotection In Patients With Chronic Heart Failure As A Consequence Of Myocardial Infarction. Periodica Journal of Modern Philosophy, Social Sciences and Humanities, 17, 137-140.